Three things happened in 1776.
One of them, you know about. It's the reason America exists.
The other two? You likely have no idea. But without them, the modern world would not exist. No capitalism. No industrial revolution. No iPhone in your pocket.
Nothing.
And the fortunes these three converging forces made are unsurpassed by any other economic event ever.
Now, almost exactly 250 years later, those same three forces are converging again.
And as you'll discover today, the aftershock of this event could 'reset' not just your personal wealth, but the entire U.S. economic system….
My name is Porter Stansberry.
I’m the founder of one of the largest financial research firms in the world. Over the last 26 years we’ve helped investors navigate almost every major economic cycle.
We’ve also been on the forefront of every big financial story from the rise of Bitcoin and MRNA vaccines to robotics and artificial intelligence – just to name a few.
But today, I’m breaking the biggest story of my career…
An economic story the likes of which we’ve not seen in centuries. In fact, the last – and only time – this happened was in 1776. But now, on the eve of America’s 250th anniversary, it’s happening again.
How you work, how you vote, how you protect and build your wealth… it’s all being turned upside down by what one famous Stanford economist says is:
“The biggest change ever… bigger than electricity… bigger than the steam engine.”
Yet almost nobody is prepared for it. So, if you’ve been watching the chaos of the past year unfold, struggling to understand what it all means… you’re about to get many - if not all - of the answers you’ve been searching for.
And, most importantly, what it all means for you, your money, and your investment portfolio in the months ahead
Because as you’ll discover, everything from the government taking stakes in companies like Intel, Lithium Americas, and MP Materials.
To Trump’s strike on Venezuela… his deal with Greenland… his seemingly never-ending slew of executive orders… and increasingly centralized grip over the economy…
All the way to the surging popularity of radical socialist politicians like Bernie Sanders, AOC, and Zohran Mamdani…
It’s all deeply and inexorably intertwined in what is, without a doubt, the most consequential story of the year.
A turning point that one Nobel Prize winner says is dividing not just the economy but our entire society.
And, as my guest and I explain, the financial decisions you make in the face of this New 1776 Moment… they could dictate whether you’re enriched, left stuck in the past, or potentially even impoverished by the seismic changes barreling down upon America.
The stocks to buy… the stocks to sell… and the three money moves to ensure you and your loved ones end up on the winning side of this new economic reality.
It’s all laid out here for you…
Good investing,
Porter Stansberry
Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
Written by Leo Miller. Originally Published: 5/21/2026.
Key Points
- Meta Platforms stock has seen large swings in 2026, being up as much as 12% and down as much as 20%
- Through recently announced layoffs, the company is looking to soothe fears around its elevated spending
- However, shares are not seeing an uptick on this news—here's why
- Special Report: Elon Musk already made me a “wealthy man”
Shares of Meta Platforms (NASDAQ: META) have experienced a notable amount of volatility in 2026. The stock started the year strong, rising roughly 12% by the end of January. The company’s impressive Q4 2025 earnings report fueled a gain of more than 10% in a single day.
However, a combination of pressures then hit the stock, including fears over artificial intelligence (AI) spending, legal setbacks, and the U.S.-Iran conflict, which weighed on the broader market. By the end of March, Meta was down 20% for the year.
Goldman Sachs just told you what to buy (most people missed it) (Ad)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up.
One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.
See the stock positioned to solve AI's biggest power crisisThe stock has recovered considerably since then and is now down less than 10% in 2026. Meta has hovered near this level since the end of April, after shares fell 8.6% following its Q1 2026 earnings report.
Meta is making moves to counter the biggest headwind to its performance: rising AI capital expenditure (CapEx) forecasts. The company is also carrying out one of its largest rounds of layoffs in recent memory in an effort to offset AI investment. Still, markets do not appear to be buying the story.
Meta Initiates 10% Layoff—But for Much Different Reasons Than in the Past
In mid-May, reports emerged that Meta is laying off 8,000 employees. These job cuts represent approximately 10% of Meta’s total workforce.
The move marks the company’s most significant workforce shake-up since its “Year of Efficiency,” which took place between 2022 and 2023. That initiative eliminated 21,000 jobs.
However, there are major differences between these recent cuts and the Year of Efficiency reductions.
Somewhat counterintuitively, Meta undertook one of its most aggressive hiring sprees ever from 2020 to 2022, during the height of the COVID pandemic.
By the end of 2022, Meta’s employee count had nearly doubled from the end of 2019, rising from around 45,000 to more than 86,000. This came as COVID lockdowns pushed people to spend much more time online and helped fuel e-commerce activity. That environment drove Meta’s sales growth to 37% year over year (YOY) in 2021.
The company added employees believing that this was the beginning of a long-term tailwind for its business. However, as Meta admitted, that did not prove to be the case, with sales falling 1% YOY in 2022. In 2023, Meta reduced its employee count by 22% to around 67,000 in response.
Meta’s past cuts were driven by weaker-than-expected demand. That is not the case today.
Meta just posted its highest revenue growth in years, up 33% YOY. Demand is clearly strong, but it is being met with heavier investment in technology rather than staff. In that sense, the move is much less a sign of weakness than the mass layoffs in the past.
Layoffs Are Unlikely to Win Over Investors' Hearts
Still, Meta shares have not moved much since the recent layoffs began. Investors likely do not believe the cuts will have a significant impact on the company’s financials.
Notably, analysts at Morgan Stanley have estimated that a 20% workforce reduction would generate annual savings of between $3 billion and $7 billion. At 10%, it is fair to say that this estimate would fall to roughly $1.5 billion to $3.5 billion.
Meta will also likely incur a significant charge to cover severance packages. When it cut 10,000 employees in March 2023, its expected pre-tax severance charge and other personnel costs were $1 billion, or about $100,000 per employee. Keeping that per-employee estimate steady, the company could incur around $800 million in charges from the latest layoff, reducing the near-term benefit.
Overall, Meta’s savings would be a drop in the bucket compared with the midpoint of its 2026 CapEx guidance of $135 billion. Furthermore, it is unclear whether Meta will simply redirect any savings from layoffs into additional AI investment or whether its CapEx guide will remain unchanged.
Either way, relative to its massive CapEx spending, the potential benefit from the layoffs is not much of a needle mover. That is likely one reason shares have not benefited. Additionally, CEO Mark Zuckerberg told employees that he “does not expect more company-wide layoffs this year."
This pushes back on past reports that the company would cut 20% of its workforce in 2026. Investors may have seen the smaller-than-expected reduction as a disappointment.
Growth Is the Key to Meta’s AI Journey
In aggregate, this data shows that Meta will not be able to justify its AI spending through layoffs alone. Instead, the company will need to grow its revenues and, eventually, its free cash flow to do so.
In this context, the fact that Meta is also reassigning 7,000 employees to AI-related roles may be more important than the layoffs themselves. After the cuts, Meta’s employee count will fall to around 71,000. That means the company will reallocate roughly 10% of its remaining workforce to AI-related roles. This increased focus on AI could help Meta better utilize its investments and support growth.
Amylyx Stock: Why the Full Pipeline Story Matters
Written by Chris Markoch. Originally Published: 5/24/2026.
Key Points
- Amylyx stock is gaining attention as multiple pipeline programs move toward important clinical milestones in 2026.
- The company’s Avexitide candidate targets post-bariatric hypoglycemia, offering a niche but potentially first-in-class GLP-1 antagonist opportunity.
- Investors may see the largest long-term upside from Amylyx’s ALS program, though commercialization remains years away.
- Special Report: Elon Musk already made me a “wealthy man”
The idiom “never judge a book by its cover” can cut both ways when it comes to clinical-stage biotechnology companies like Amylyx Pharmaceuticals (NASDAQ: AMLX). The stock is up more than 140% over the last 12 months as the company has advanced its pipeline.
One of the drugs in that pipeline is Avexitide, a treatment for post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. In early May, Amylyx announced it had completed full enrollment in its Phase 3 trial, LUCIDITY. Topline results are expected in Q3 2026, which is pivotal for AMLX’s short-term outlook.
What Musk is quietly building behind the SpaceX headlines (Ad)
Before SpaceX dominates every headline, there's a bigger story forming behind the scenes. Elon Musk has quietly assembled a global network - hundreds of locations, thousands of autonomous systems - all designed to power what analyst Matt McCall calls 'AI Everywhere.'
It's already expanding, and most investors haven't connected the dots yet. McCall just recorded a free presentation breaking down what this buildout means, why it could reshape the market, and how to position early.
Watch the full presentation now before this becomes a mainstream storyHowever, this is a story that’s playing out in three distinct chapters that will take years to fully develop. And, as is the case with even large-cap biotech companies, execution is always a risk. Investors saw that with another company, Regeneron Pharmaceuticals (NASDAQ: REGN), on May 18, when it delivered Phase 3 results for its melanoma study of fianlimab + Libtayo that failed to meet its primary endpoint versus Keytruda, the industry standard from Merck & Co. (NYSE: MRK).
That said, positive news is positive news. Amylyx is committed to developing treatments for diseases with high unmet needs. Here’s a full read on the company’s progress as of late May 2026.
Chapter 1: A GLP-1 Contrarian Play
Amylyx is taking the opposite approach to the GLP-1 boom: instead of developing agonists for weight loss, the company is developing a GLP-1 antagonist. Avexitide is a first-in-class GLP-1 antagonist that could become the first-ever FDA-approved therapy for post-bariatric hypoglycemia (PBH). This is a metabolic condition that affects approximately 8% of patients in the United States who have undergone one of the two most common types of bariatric surgery.
A key consideration for investors is that PBH has a small addressable market of around 160,000. So while it’s addressing the GLP-1 market, it’s doing so in a niche fashion. That doesn’t make it any less relevant. But if investors are going to look at Amylyx with conviction, they’ll need to take a wider view.
Chapter 2: An Important Proof of Concept
Next in the company’s pipeline is AMX0035, the company’s therapeutic for Wolfram syndrome. This is a rare genetic disease that presents significant challenges for patients. It usually begins in childhood with insulin-requiring diabetes and is marked by progressive optic nerve changes that affect vision and can involve broader neurological symptoms that increasingly affect daily life.
The addressable global market is estimated to be about 15,000 to 30,000 patients, with about 1,000 to 2,000 in the United States. AMX0035 is in its Phase 2 HELIOS trial, and Amylyx has already delivered positive results at both the Week 24 and Week 48 milestones. The company plans to share Week 96 data later this year.
This is an incredibly small market, but it can serve as proof of how Amylyx can treat neurodegenerative diseases, which is where the plot thickens.
Chapter 3: When the Plot Really Takes Off
Further back in the company’s pipeline is AMX0114, the company’s treatment for ALS. The global ALS therapeutics market is expected to reach $1.7 billion in 2034 and is growing at a compound annual growth rate (CAGR) of 10%. This is a market with essentially no disease-modifying options, which gives pricing power to companies that develop anything that demonstrably works.
Amylyx completed enrollment of Cohort 2 of its ongoing Phase 1 trial in March 2026, with early biomarker data from Cohort 1 expected in June 2026. Significantly, the drug carries FDA Fast Track designation, and the early readouts have been positive.
But this is still a drug in its early phases. It will be 2029 or 2030 at the earliest before investors have a line of sight on commercial production.
Time Is Your Friend
Investors who plan to hold AMLX for the long haul can build a position over time. One idea is to divide a position into thirds and allocate one-third of the capital to each pipeline milestone.
That way, investors can capture the potential upside with less downside risk. The Amylyx analyst forecasts on MarketBeat give the stock a consensus price target of $23, a gain of more than 60% from its opening price on May 21. But that implies that the results the company is expected to deliver later this year will be positive.
It’s also important to note that AMLX has about 15% short interest, which is meaningful given the stock's 20% decline over the 30 days ending May 20. That reflects the recent earnings report, which served as a reminder that the company is not profitable and has not yet generated revenue.
The company is a niche play today. Whether it is being priced for its future growth remains to be seen. Like many biotech stocks, Amylyx has risk, but the upside may be worth a speculative position.
This email communication is a sponsored message for Porter & Company, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions or concerns about your newsletter, please contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103. U.S.A..
Post a Comment
0Comments